TY - JOUR
T1 - Stereotactic body radiation therapy
T2 - A promising chance for oligometastatic breast cancer
AU - Scorsetti, Marta
AU - Franceschini, Davide
AU - De Rose, Fiorenza
AU - Comito, Tiziana
AU - Villa, Elisa
AU - Iftode, Cristina
AU - Navarria, Pierina
AU - D'Agostino, Giuseppe Roberto
AU - Masci, Giovanna
AU - Torrisi, Rosalba
AU - Testori, Alberto
AU - Tinterri, Corrado
AU - Santoro, Armando
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Background: Multidisciplinary management of oligometastatic breast cancer with local therapy could improve disease control. The aim of our study is the assessment of safety and efficacy of Stereotactic Body Radiation Therapy (SBRT) in selected subset of patients. Patients and methods: Oligometastastic patients from breast cancer were treated with SBRT for 1-3 lung and liver lesions, in an observational study. Inclusion criteria were: age >18 years, ECOG 0-2, diagnosis of breast cancer, no extrapulmonary and/or extrahepatic disease, other metastatic sites stable or responding after chemotherapy were allowed, no life threatening conditions, less than 5 lung and liver lesions (with maximum diameter 12 months, hormonal receptor positivity, medical therapies after SBRT showed a significant impact on OS. Treatment was well tolerated, with no G3-4 toxicities. Conclusions: SBRT is a safe and feasible alternative treatment of liver and lung oligometastases from breast cancer, in selected patients not amenable to surgery, with good local control and survival rate.
AB - Background: Multidisciplinary management of oligometastatic breast cancer with local therapy could improve disease control. The aim of our study is the assessment of safety and efficacy of Stereotactic Body Radiation Therapy (SBRT) in selected subset of patients. Patients and methods: Oligometastastic patients from breast cancer were treated with SBRT for 1-3 lung and liver lesions, in an observational study. Inclusion criteria were: age >18 years, ECOG 0-2, diagnosis of breast cancer, no extrapulmonary and/or extrahepatic disease, other metastatic sites stable or responding after chemotherapy were allowed, no life threatening conditions, less than 5 lung and liver lesions (with maximum diameter 12 months, hormonal receptor positivity, medical therapies after SBRT showed a significant impact on OS. Treatment was well tolerated, with no G3-4 toxicities. Conclusions: SBRT is a safe and feasible alternative treatment of liver and lung oligometastases from breast cancer, in selected patients not amenable to surgery, with good local control and survival rate.
KW - Breast cancer
KW - Liver
KW - Lung
KW - RapidArc
KW - Stereotactic body radiation therapy
UR - http://www.scopus.com/inward/record.url?scp=84961841977&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961841977&partnerID=8YFLogxK
U2 - 10.1016/j.breast.2015.12.002
DO - 10.1016/j.breast.2015.12.002
M3 - Article
AN - SCOPUS:84961841977
VL - 26
SP - 11
EP - 17
JO - Breast
JF - Breast
SN - 0960-9776
ER -